Epileptic encephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:07 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Epileptic encephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Elsunersen in Children with SCN2A Developmental and Epileptic Encephalopathy to Reduce Seizures https://clinicaltrials.eu/trial/study-of-elsunersen-in-children-with-scn2a-developmental-and-epileptic-encephalopathy-to-reduce-seizures/ Wed, 29 Apr 2026 15:07:28 +0000 https://clinicaltrials.eu/trial/study-of-elsunersen-in-children-with-scn2a-developmental-and-epileptic-encephalopathy-to-reduce-seizures/ This study focuses on children with SCN2A developmental and epileptic encephalopathy (DEE), a rare genetic condition that causes severe seizures starting in early infancy. The research evaluates a new medication called PRAX-222 (elsunersen), which is given as an injection into the spinal fluid through a procedure called intrathecal administration. The purpose is to determine if this treatment can reduce the frequency of seizures in children with this specific genetic condition.

The study uses a double-blind design where some participants receive the study medication while others undergo a sham procedure. The treatment period lasts 24 weeks, during which participants receive regular doses of the medication. Throughout the study, doctors monitor how often seizures occur and track any changes in the participants’ overall condition.

During the trial, participants continue their regular seizure medications while receiving the study treatment. The study medication is administered at specific intervals over the course of treatment, with a maximum daily dose of 1 mg and a total maximum dose of 12 mg over 48 weeks. Doctors closely monitor participants’ health through regular check-ups, including evaluations of their physical condition, neurological status, and laboratory tests.

]]> Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy https://clinicaltrials.eu/trial/study-of-intrathecal-s230815-to-evaluate-safety-and-effectiveness-in-children-with-kcnt1-related-developmental-and-epileptic-encephalopathy/ Wed, 29 Apr 2026 15:07:25 +0000 https://clinicaltrials.eu/trial/study-of-intrathecal-s230815-to-evaluate-safety-and-effectiveness-in-children-with-kcnt1-related-developmental-and-epileptic-encephalopathy/ This study focuses on children with KCNT1-related Developmental and Epileptic Encephalopathy, a rare genetic condition that causes severe epilepsy and developmental delays in young children. The study will test a new medication called S230815, which is given through an injection into the spinal fluid. This medication is designed to target a specific gene called KCNT1 that is involved in causing this type of epilepsy.

The purpose of this research is to determine if the medication is safe and how well children’s bodies process it. The study will involve multiple doses of the medication, with the amount being gradually increased over time. The medication is being tested for the first time in humans, specifically in children between 2 and 12 years of age who have confirmed genetic changes in the KCNT1 gene.

During the study, participants will receive the medication through intrathecal injections (delivered directly into the fluid surrounding the spinal cord). The medication is an antisense oligonucleotide, which is a type of drug that can reduce the activity of specific genes. Throughout the study, doctors will monitor how the children respond to the treatment and check for any side effects.

]]> Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bexicaserin-for-seizures-in-children-and-adults-with-developmental-and-epileptic-encephalopathy/ Wed, 29 Apr 2026 15:05:57 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bexicaserin-for-seizures-in-children-and-adults-with-developmental-and-epileptic-encephalopathy/ This clinical trial is focused on studying a group of conditions known as Developmental and Epileptic Encephalopathies (DEEs). These are severe brain disorders that start in childhood and are characterized by frequent seizures and developmental delays. The study is investigating a treatment called bexicaserin, also known by its code name LP352. This medication is given as an oral solution, which means it is taken by mouth in liquid form.

The purpose of the study is to evaluate the long-term safety and effectiveness of bexicaserin in treating seizures in both children and adults with DEEs. Participants in the study will receive the medication over a period of time, and researchers will monitor them to see how well they tolerate the treatment and whether it helps reduce the frequency of seizures. The study will also involve regular check-ups, including physical exams and tests to monitor health indicators like heart rate and weight.

Throughout the study, participants will be asked to keep a diary of their seizures to help researchers understand how the treatment is working. The study aims to provide valuable information on the potential benefits and safety of bexicaserin for people living with Developmental and Epileptic Encephalopathies.

]]> Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies https://clinicaltrials.eu/trial/study-on-the-effects-of-bexicaserin-for-seizures-in-children-and-adults-with-developmental-and-epileptic-encephalopathies/ Wed, 29 Apr 2026 15:05:40 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-bexicaserin-for-seizures-in-children-and-adults-with-developmental-and-epileptic-encephalopathies/ This study focuses on Developmental and Epileptic Encephalopathies (DEE), a group of severe conditions that cause frequent seizures and affect brain development. The research evaluates a new medication called LP352 (bexicaserin), which is given as an oral solution. The study aims to determine if this medication can effectively reduce seizures in children and adults with this condition.

The study uses LP352 or placebo in the form of an oral solution, which can be given through the mouth or through a feeding tube. Participants will take the medication or placebo for approximately 17 weeks. The maximum daily dose of the medication is 36 milligrams, and participants will continue taking their regular anti-seizure medications during the study.

The research focuses on people who experience various types of seizures, including tonic seizures (stiffening of muscles), atonic seizures (sudden loss of muscle strength), focal seizures (seizures that start in one part of the brain), and tonic-clonic seizures (convulsions with both stiffening and jerking). The study particularly includes people with Lennox-Gastaut Syndrome, a severe form of epilepsy that begins in childhood.

]]> Study on PRAX-562 for Children with Developmental and Epileptic Encephalopathies https://clinicaltrials.eu/trial/study-on-prax-562-for-children-with-developmental-and-epileptic-encephalopathies/ Wed, 29 Apr 2026 14:24:19 +0000 https://clinicaltrials.eu/trial/study-on-prax-562-for-children-with-developmental-and-epileptic-encephalopathies/ This clinical trial is focused on studying a group of rare conditions known as developmental and epileptic encephalopathies (DEEs), specifically those related to genetic changes in the SCN2A and SCN8A genes. These conditions are characterized by severe epilepsy and developmental delays in children. The trial is testing a new treatment called PRAX-562, which is a powder that can be taken by mouth. The purpose of the study is to explore the safety and how well children tolerate this new treatment, as well as its effects on reducing the frequency of seizures.

The study is divided into two parts. In the first part, participants will be randomly assigned to receive either PRAX-562 or a placebo, which looks like the treatment but does not contain the active substance. This part of the study is double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment. The second part of the study is an open-label extension, where all participants will receive PRAX-562. This allows researchers to gather more information about the long-term safety and effects of the treatment.

Participants in the study will be children aged 2 to 18 years who have been diagnosed with SCN2A or SCN8A related DEEs. The study will monitor the number of seizures the children experience and any side effects they may have while taking the treatment. The trial aims to provide valuable insights into the potential benefits of PRAX-562 for children with these challenging conditions.

]]>